1-4 of 4
erythema nodosum leprosum
Close
Sort by
Journal Articles

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Abdullah Kutlar, MD, Paul S. Swerdlow, MD, Steffen E. Meiler, MD, Kavita Natrajan, MBBS, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Sheetal Shah, BA, Robert Knight, MD
Journal: Blood
Blood (2013) 122 (21): 777.
https://doi.org/10.1182/blood.V122.21.777.777
Published: 2013
Journal Articles

The Importance of Press Releases Describing ASH Conference Findings in Translating Research Into Policy: Case Study and Seven-Year Follow-up From a 2004 Oral Presentation

Charles Bennett, MD, PhD, MPP, Adam Kahn, Zaina Parvez Qureshi, PhD, MPH, Sudha Xirasagar, MBBS, PhD, Donald Mattison, M.D., CAPT, USPHS
Journal: Blood
Blood (2011) 118 (21): 4766.
https://doi.org/10.1182/blood.V118.21.4766.4766
Published: 2011
Journal Articles

Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide’s “Off-Label” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.

Andrew M. Evens, DO, MS, June M. McKoy, MD, MPH, JD, Paul R. Yarnold, PhD, Kathyrn McCaffrey, BA, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2005) 106 (11): 2244.
https://doi.org/10.1182/blood.V106.11.2244.2244
Published: 2005
Journal Articles

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Andrew M. Evens, DO, Martin S. Tallman, MD, Seema Singhal, MD, June M. McKoy, MD, JD, E. Allison Lyons, BA, Dennis W. Raisch, PhD, Paul R. Yarnold, PhD, Hau Kwaan, MD, Timothy M. Kuzel, MD, Jayesh Mehta, MD, Charles L. Bennett, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 265.
https://doi.org/10.1182/blood.V104.11.265.265
Published: 2004